Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Average sales price and wholesale acquisition cost
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Average sales price and wholesale acquisition cost

1 evidence topic · 1 source

United States average sales price and wholesale acquisition cost

No evidence found.

Medical costs: Japan

“Medical costs were calculated based on Japanese receipt scores.” (opens the source at this quote in a new tab)
“tirabrutinib cost 0.91 million JPY per month.” (opens the source at this quote in a new tab)